Program
eloralintide
Also written as “Eloralintide”, “LY3841136” and “eloralintide and tirzepatide”.
Its studies are mostly in Obesity · Osteoarthritis · Sleep Apnea, Obstructive · Kidney Failure, Chronic · Hepatic Insufficiency, led by Eli Lilly.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lilly | 2619 open or running | phase 3since Dec 5, 2025 | Mar 24, 2022 | Dec 2026phase 1 · NCT07738614 |
- Named in Eli Lilly’s own pipeline as
Eloralintide
, phase 3, as of Oct 29, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 3 studies since Mar 24, 2022.
- Mar 1, 20242 phase 1 studies in ObesityNCT06297616, NCT06345066
- Sep 17, 2024Phase 2 study in ObesityNCT06603571 · 367 enrolled · United States, Argentina
- Apr 1, 20252 phase 1 studiesNCT06916091, NCT06916065
- Oct 9, 2025Phase 2 study in ObesityNCT07215559 · 200 enrolled · United States, Argentina, Australia and more
- Dec 5, 2025Phase 3 study in OverweightPhase 3 reachedNCT07282600 · 1,035 planned · United States, China, Czechia and more
- Jan 5, 20264 phase 3 studiesNCT07321886, NCT07353931, NCT07369011 and 1 more
- Feb 4, 20262 phase 1 studiesNCT07401862, NCT07426380
- May 11, 2026Phase 2 study in OverweightNCT07589608 · 400 planned · United States
- Jun 19, 2026Phase 1 study in OverweightNCT07665879 · 115 planned · Germany, Sweden
- Jul 9, 20262 phase 1 studiesNCT07701083, NCT07738614
- Aug 11, 2026Phase 1 study in ObesityNCT07765511 · 60 planned · Japan
- Sep 3, 2026Phase 1 study in ObesityNCT07808060 · 34 planned · United States
- Oct 12, 20263 phase 3 studies in ObesityNCT07881458, NCT07881432, NCT07900633
- Nov 9, 2026Phase 1 study in HealthyNCT07935304 · 90 planned · United States, Singapore
Ahead
- Dec 2026Primary completion: phase 1 study in ObesityNCT07738614
- Mar 2027Primary completion: phase 1 study in Hepatic InsufficiencyNCT07401862
- Mar 2027Primary completion: phase 2 study in ObesityNCT07215559
- Apr 2027Primary completion: phase 1 study in HealthyNCT07935304
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 26 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07935304Healthy · United States, Singapore | 1 | Not yet recruiting | Apr 2027 | 90 |
| NCT07900633Obesity · United States, Argentina, Australia and more | 3 | Not yet recruiting | Nov 2029 | 3,000 |
| NCT07881458Obesity · United States, Brazil, China and more | 3 | Recruiting | Oct 2029 | 1,000 |
| NCT07881432Obesity · United States, Argentina, China and more | 3 | Not yet recruiting | Oct 2029 | 2,115 |
| NCT07808060Obesity · United States | 1 | Recruiting | Jun 2027 | 34 |
| NCT07765511Obesity · Japan | 1 | Not yet recruiting | Jun 2027 | 60 |
| NCT07738614Obesity · United States, Singapore | 1 | Recruiting | Dec 2026 | 56 |
| NCT07701083Healthy Volunteers · United States | 1 | Active, not recruiting | Oct 2026 | 58 |
| NCT07665879Overweight · Germany, Sweden | 1 | Recruiting | Aug 2027 | 115 |
| NCT07589608Overweight · United States | 2 | Recruiting | Sep 2027 | 400 |
| NCT07426380Kidney Diseases · United States | 1 | Active, not recruiting | Oct 2026 | 28 |
| NCT07401862Hepatic Insufficiency · United States, Hungary | 1 | Recruiting | Mar 2027 | 36 |
| NCT07392190Overweight · United States, Australia, Belgium and more | 3 | Recruiting | Jun 2028 | 900 |
| NCT07369011Sleep Apnea, Obstructive · United States, Australia, Brazil and more | 3 | Recruiting | Mar 2028 | 800 |
| NCT07353931Osteoarthritis · United States, Argentina, Belgium and more | 3 | Recruiting | Mar 2028 | 900 |
| NCT07321886Obesity · United States, Argentina, Australia and more | 3 | Recruiting | Mar 2028 | 1,980 |
| NCT07282600Overweight · United States, China, Czechia and more | 3 | Recruiting | Jan 2028 | 1,035 |
| NCT07215559Obesity · United States, Argentina, Australia and more | 2 | Active, not recruiting | Mar 2027 | 200 |
| NCT06916091Obesity · Singapore | 1 | Completed | Sep 9, 2025 | 30 |
| NCT06916065Overweight · United States | 1 | Completed | Jan 19, 2026 | 188 |
| NCT06603571Obesity · United States, Argentina | 2 | Completed | Jul 1, 2026 | 367 |
| NCT06345066Obesity · United States | 1 | Completed | Sep 29, 2025 | 96 |
| NCT06297616Obesity · Japan | 1 | Completed | Nov 21, 2025 | 128 |
| NCT06230523Obesity · United States | 2 | Completed | May 30, 2025 | 263 |
| NCT06143956Obesity · United States, Argentina | 2 | Recruiting | Sep 2027 | 1,481 |
| NCT05295940Obesity · United States | 1 | Completed | Jan 25, 2024 | 148 |
How it is read
Names in the registry
- “Eloralintide”, 19 entries
- “LY3841136”, 7 entries
- “eloralintide and tirzepatide”, 2 entries
- “Eloralintide and Tirzepatide”, 1 entry
Conditions, from the studies’ own filings
- Obesity, 20 studies
- Osteoarthritis, 1 study
- Sleep Apnea, Obstructive, 1 study
- Kidney Failure, Chronic, 1 study
- Hepatic Insufficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.